Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 17.72 -0.75 (-4.06%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Travere Therapeutics Inc < Previous 1 2 3 4 Next > Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 13, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares November 12, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Pricing of Public Offering of Common Stock November 07, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Proposed Public Offering of Common Stock November 07, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences November 04, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Third Quarter 2024 Financial Results October 31, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 October 26, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Third Quarter 2024 Financial Results October 21, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy October 17, 2024 Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 October 14, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm October 11, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up September 26, 2024 Company to host conference call today at 4:30 p.m. ET From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 12, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference September 10, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 05, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 August 22, 2024 Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences August 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024 August 02, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Travere Therapeutics Reports Second Quarter 2024 Financial Results August 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Second Quarter 2024 Financial Results July 25, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy April 24, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International April 04, 2024 Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association April 03, 2024 Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) From Travere Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
